Want to see BRKR full AI Analyst Report?
Revenue by Segment
Breaks down sales across Bruker’s product and service lines, highlighting the main growth drivers such as instruments, consumables, or service contracts. Signals reliance on particular businesses, the balance between one-time equipment sales and recurring revenue, and areas with the most upside or vulnerability.Post-2023 segment reshuffle, revenue growth is concentrated in CALID and NANO — both show steady, multi-quarter gains — while BioSpin is more volatile and sensitive to lumpy system sales and China/academic weakness. BEST remains a smaller but stabilizing franchise thanks to recent multi-year orders. Management’s strong BSI bookings and book-to-bill >1, plus M&A and outsized cost savings, argue for near-term margin recovery and a return to organic growth, but investors should monitor BioSpin lumpiness and China/academic demand as the key downside risks.
Date | Eliminations | BSI BioSpin | BSI CALID | BSI Life Science | BSI NANO | BEST |
|---|---|---|---|---|---|---|
Jun 30, 2026 | -$300.00K | $195.70M | $310.30M | $0.00 | $261.30M | $74.20M |
Mar 31, 2026 | -$3.20M | $197.50M | $316.30M | $0.00 | $246.00M | $66.80M |
Dec 31, 2025 | -$2.00M | $267.00M | $331.60M | $0.00 | $309.10M | $71.50M |
Sep 30, 2025 | -$1.20M | $208.70M | $312.70M | $0.00 | $266.50M | $73.80M |
Jun 30, 2025 | -$2.10M | $195.30M | $285.80M | $0.00 | $252.10M | $66.30M |
Mar 31, 2025 | -$2.40M | $207.80M | $280.10M | $0.00 | $256.60M | $59.30M |
Dec 31, 2024 | -$3.80M | $282.40M | $320.60M | $0.00 | $318.30M | $72.10M |
Sep 30, 2024 | -$3.80M | $223.00M | $279.40M | $0.00 | $287.10M | $68.70M |
Jun 30, 2024 | -$4.00M | $217.50M | $265.60M | $0.00 | $252.50M | $69.10M |
Mar 31, 2024 | -$2.50M | $182.80M | $227.90M | $0.00 | $240.40M | $73.10M |